Alzheimer's disease

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on: 
Mercoledì, Aprile 10, 2024
Tsinghua University, OCTA, Alzheimer's disease, Finance, CE, Patient, Artificial intelligence, Adolescence, World's fair, Medical device regulation, Dementia, CNV, Certification, Hyperthyroidism, HK, Partnership, Policy, MICCAI, Safety, Lighting, Optical coherence tomography angiography, Intelligence, Choroidal neovascularization, Journal, Hospital, Research, Near-sightedness, Amblyopia, AI, Insurance, Strabismus, AMD, Gold medal, Diagnosis, Peking University, Conference, Growth, Biomarker, Plaque, News, Bleeding, Google Images, Rehabilitation, Medical device

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points: 
  • Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
    On March 27, medical artificial intelligence company Airdoc Technology (2251.
  • In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
  • In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
  • In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.

AskBio Names Mansuo Shannon Chief Scientific Officer

Retrieved on: 
Martedì, Aprile 9, 2024
Eli Lilly, Alzheimer's disease, Gene editing, Princeton University, MIT, Research, Bayer, Chugai Pharmaceutical Co., Doctor of Philosophy, Samulski, Therapy, Eli Lilly and Company, CSO, Molecular biology, Management

Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Key Points: 
  • Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
    Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
    Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that on April 8, 2024, Mansuo Shannon, PhD, was named the company’s next Chief Scientific Officer (CSO).
  • Shannon joins AskBio from Prevail Therapeutics, where she also served as CSO.
  • Reporting to Gustavo Pesquin, Chief Executive Officer (CEO), Shannon will be a member of AskBio’s Executive Leadership Team and head its R&D organization.
  • As part of her role as CSO at AskBio, Shannon will develop and implement the company’s future R&D strategy.

Is Sundown Syndrome Taking Over Your Evenings? Michele Nealon, Psy.D. Shares Expert Tips to Manage the Symptoms

Retrieved on: 
Martedì, Aprile 9, 2024
Health, Agitation, Sleep apnea, Alzheimer's disease, Confusion, Exercise, Chicago school, Hunger, Depression, Caregiver, Diabetes, Empathy, Stroke, Sleep, Mental health, Sundowning, Anxiety, Frustration, Dementia, Medicine, Residential care

Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.

Key Points: 
  • Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.
  • This syndrome's cause is not well understood, but we know it can take a toll on the individual and their caregivers.
  • Setting a schedule of regular exercise, a healthy diet, and quality sleep for you and the person you are taking care of is imperative.
  • Patience and empathy are key when trying to ease their agitation because it can worsen if they sense your frustration.

Clearday to Host a Solar Watch Event– the Event of the Decade occurs today. A total Solar Eclipse is ready to travel from Texas to Maine.

Retrieved on: 
Lunedì, Aprile 8, 2024
Eclipse, Astronomy, Sun, Innovation, Alzheimer's disease, Club, Disease, Risk, Sun Chips, Moon, OTCQX, Solar eclipse, Dementia, Nightclub

San Antonio, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Clearday (OTCQX CLRD) is pleased to announce that Clearday Club Leon Valley is hosting a watch event for the Solar Eclipse.

Key Points: 
  • San Antonio, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Clearday (OTCQX CLRD) is pleased to announce that Clearday Club Leon Valley is hosting a watch event for the Solar Eclipse.
  • The Clubs’ Solar Eclipse event will highlight engagement activities involving astronomy with a focus on the Stars, the Sun and the Moon!
  • We are planning the day’s menu around the sun as a theme – such as Sun Chips, raisins and Sunkissed products.
  • The Clearday Club is membership-based, offering an inspiring new kind of daytime destination for those with lifestyle-limiting chronic health conditions.

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Venerdì, Aprile 5, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Telephone, Patient, Defendant, City University, Journal, Biomarker, News, Scientific misconduct, Complaint, P.C, Neurobiology of Aging, Cognition, Safety, Data management, FDA, Pharmaceutical industry

Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Giovedì, Marzo 28, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Patient, City University, Journal, Biomarker, News, LLP, Scientific misconduct, Neurobiology of Aging, Cognition, Safety, Advertising, Data management, FDA, Court, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Marzo 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Martedì, Marzo 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Retrieved on: 
Martedì, Aprile 9, 2024
Psilocybin, Alzheimer's disease, Partnership, Research, Parkinson's disease, Inflammatory bowel disease, Therapy, Intellectual property, Bryostatin, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul").
  • Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics.
  • Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").
  • Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors.

Pacing Toward Progress: Dr. Daniel Corcos' Trailblazing Research Reveals Exercise's Potential to Slow Parkinson's Disease Progression

Retrieved on: 
Lunedì, Aprile 8, 2024
Exercise, Disease, PD, Alzheimer's disease, Risk, Patient, Heart rate, State, Observation, Parkinson's disease, Woman, Cognition, Principal investigator, Urban, Neurodegenerative disease, Pharmaceutical industry

As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.

Key Points: 
  • As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.
  • Moreover, men are 1.5 times more likely to develop Parkinson's disease than women.
  • Three recent studies, suggests that endurance exercise may offer a significant breakthrough in Parkinson's treatment in that the suggest that exercising at 80% of maximum heart rate may slow disease progression.
  • Dr. Corcos underscores the indispensable role of aerobic exercise in Parkinson's treatment, citing evidence suggesting its potential to slow disease progression.